p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: A prospective series

Journal of Clinical Oncology

Volumn 18, Issue 7, 2000, Pages 1465-1473

  Cabelguenne, Arnauld ^a   Blons, Hélène ^a   de Waziers, Isabelle ^a   Carnot, Françoise ^a   Houllier, Anne Marie ^a   Soussi, Thierry ^a   Brasnu, Daniel ^a   Beaune, Phillipe ^a   Laccourreye, Ollivier ^a   Laurent Puig, Pierre ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CHROMOSOME 17P; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE MUTATION; HEAD AND NECK CANCER; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; TUMOR SUPPRESSOR GENE;

EID: 0034086197     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.7.1465     Document Type: Article

References (48)

1. Catimel G: Head and neck cancer: Guidelines for chemotherapy. Drugs 51:73-88, 1996
2. Kish JA, Ensley JF, Jacobs J, et al: A randomized trial of cisplatin (CACP) + 5-fluorouracil (5-FU) infusion and CACP + 5-FU bolus for recurrent and advanced squamous cell carcinoma of the head and neck. Cancer 56:2740-2744, 1985
3. Thyss A, Schneider M, Santini J, et al: Induction chemotherapy with cis-platinum and 5-fluorouracil for squamous cell carcinoma of the head and neck. Br J Cancer 54:755-760, 1986
4. Bernal AG, Cruz JJ, Sanchez P, et al: Four-day continuous infusion of cisplatin and 5-fluorouracil in head and neck cancer. Cancer 63:1927-1930, 1989
5. The Department of Veterans Affairs Laryngeal Cancer Study Group: Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer: The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med 324:1685-1690, 1991
6. Spaulding MB. Castillo M, Lore J, et al: Surgery vs chemotherapy plus surgery for carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 118:248-251, 1992
7. Spaulding MB, Fischer SG, Wolf GT: Tumor response, toxicity, and survival after neoadjuvant organ-preserving chemotherapy for advanced laryngeal carcinoma: The Department of Veterans Affairs Cooperative Laryngeal Cancer Study Group. J Clin Oncol 12:1592-1599, 1994
8. Wolf GT, Makuch RW, Baker SR: Predictive factors for tumor response to preoperative chemotherapy in patients with head and neck squamous carcinoma: The Head and Neck Contracts Program. Cancer 54:2869-2877, 1984
9. Bachaud JM, David JM, Shubinski RE, et al: Predictive factors of a complete response to and adverse effects of a CDDP-5FU combination as primary therapy for head and neck squamous carcinomas. J Laryngol Otol 107:924-930, 1993
10. Cho Y. Gorina S, Jeffrey PD, et al: Crystal structure of p53 tumor suppressor-DNA complex: Understanding tumorigenic mutation. Science 265:334-335, 1994
11. Lane DP: Cancer: p53, guardian of the genome. Nature 358:15-16, 1992
12. Eastman A: Activation of programmed cell death by anticancer agents: Cisplatin as a model system. Cancer Cells 2:275-280, 1990
13. Lowe SW, Ruley HE, Jacks T, et al: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957-967, 1993
14. Lowe SW, Bodis S, McClatchey A, et al: p53 status and the efficacy of cancer therapy in vivo. Science 266:807-810, 1994
15. Fan S, el-Deiry WS, Bae I, et al: p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res 54:5824-5830, 1994
16. Fujiwara T. Grimm EA, Mukhopadhyay T, et al: Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res 54:2287-2291, 1994
17. Aas T, Borresen AL, Geisler S, et al: Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 2:811-814, 1996
18. Bergh J, Norberg T, Sjogren S, et al: Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med 1:1029-1034, 1995
19. Perego P, Giarola M, Righetti SC, et al: Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res 56:556-562, 1996
20. Ribeiro U Jr, Finkelstein SD, Safatle-Ribeiro AV, et al: p53 sequence analysis predicts treatment response and outcome of patients with esophageal carcinoma. Cancer 83:7-18, 1998
21. Benhattar J, Cerottini JP. Saraga E, et al: p53 mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas. Int J Cancer 69:190-192, 1996
22. Scholnick SB, Sun PC, Shaw ME, et al: Frequent loss of heterozygosity for Rb, TP53, and chromosome arm 3p, but not NME1 in squamous cell carcinomas of the supraglottic larynx. Cancer 73:2472-2480, 1994
23. Beahrs O, Henson DE, Huters RVP (eds): Manual for Staging of Cancer (ed 3). Philadelphia, PA, Lippincott, 1988, pp 39-44
24. Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982
25. Hamelin R. Jego N, Laurent-Puig P, et al: Efficient screening of p53 mutations by denaturing gradient gel electrophoresis in colorectal tumors. Oncogene 8:2213-2220, 1993
26. Guldberg P, Nedergaard T, Nielsen HJ, et al: Single-step DGGE-based mutation scanning of the p53 gene: Application to genetic diagnosis of colorectal cancer. Hum Mutat 9:348-355, 1997
27. Lubin R, Schlichtholz B, Teillaud JL, et al: p53 antibodies in patients with various types of cancer: Assay, identification, and characterization. Clin Cancer Res 1:1463-1469, 1995
28. Brachman DG, Graves D. Vokes E. et al: Occurrence of p53 gene deletions and human papilloma virus infection in human head and neck cancer. Cancer Res 52:4832-4836, 1992
29. Boyle JO, Hakim J, Koch W, et al: The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res 53:4477-4480, 1993
30. Somers KD, Merrick MA, Lopez ME, et al: Frequent p53 mutations in head and neck cancer. Cancer Res 52:5997-6000, 1992
31. Kropveld A, Slootweg PJ, van Mansfeld AD, et al: Radioresistance and p53 status of T2 laryngeal carcinoma: Analysis by immunohistochemistry and denaturing gradient gel electrophoresis. Cancer 78:991-997, 1996
32. Ahomadegbe JC, Barrois M, Fogel S, et al: High incidence of p53 alterations (mutation, deletion, overexpression) in head and neck primary tumors and metastases: Absence of correlation with clinical outcome - Frequent protein overexpression in normal epithelium and in early non-invasive lesions. Oncogene 10:1217-1227, 1995
33. Greenblatt MS, Bennett WP, Hollstein M, et al: Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855-4878, 1994
34. el-Naggar AK, Lai S, Luna MA, et al: Sequential p53 mutation analysis of pre-invasive and invasive head and neck squamous carcinoma. Int J Cancer 64:196-201, 1995
35. Lenz HJ, Hayashi K. Salonga D, et al: p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: An analysis of response and survival. Clin Cancer Res 4:1243-1250, 1998
36. Gallagher WM, Cairney M, Schott B, et al: Identification of p53 genetic suppressor elements which confer resistance to cisplatin. Oncogene 14:185-193, 1997
37. Houldsworth J, Xiao H, Murty VV, et al: Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation. Oncogene 16:2345-2349, 1998
38. Hsiao M, Low J, Dorn E, et al: Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness. Am J Pathol 145:702-714, 1994
39. Dittmer D, Pati S, Zambetti G, et al: Gain of function mutations in p53. Nat Genet 4:42-46, 1993
40. Erber R, Conradt C, Homann N, et al: TP53 DNA contact mutations are selectively associated with allelic loss and have a strong clinical impact in head and neck cancer. Oncogene 16:1671-1679, 1998
41. Hamilton TC, Winker MA, Louie KG, et al: Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion. Biochem Pharmacol 34:2583-2586, 1985
42. Ishikawa T, Ali-Osman F: Glutathione-associated cis-diamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells: Molecular characterization of glutathione-platinum complex and its biological significance. J Biol Chem 268:20116-20125, 1993
43. Kelley SL, Basu A, Teicher BA, et al: Overexpression of metallothionein confers resistance to anticancer drugs. Science 241:1813-1815, 1988
44. Kirihara Y, Yamamoto W, Toge T, et al: Dihydropyrimidine dehydrogenase, multidrug resistance-associated protein, and thymidylate synthase gene expression levels can predict 5- fluorouracil resistance in human gastrointestinal cancer cells. Int J Oncol 14:551-556, 1999
45. Ishikawa Y, Kubota T, Otani Y, et al: Dihydropyrimidine dehydrogenase activity and messenger RNA level may be related to the antitumor effect of 5-fluorouracil on human tumor xenografts in nude mice. Clin Cancer Res 5:883-889, 1999
46. Davidoff AM, Iglehart JD, Marks JR: Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. Proc Natl Acad Sci U S A 89:3439-3442, 1992
47. Winter SF, Minna JD, Johnson BE, et al: Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res 52:4168-4174, 1992
48. von Brevern MC, Hollstein MC, Cawley HM, et al: Circulating anti-p53 antibodies in esophageal cancer patients are found predominantly in individuals with p53 core domain mutations in their tumors. Cancer Res 56:4917-4921, 1996